Can I Take Glycine with Prolia (Denosumab)?

What Is Denosumab and Who Uses It?

Denosumab (brand name Prolia) is a fully human monoclonal antibody that targets RANK ligand (RANKL), a protein that drives osteoclast formation and activity. By binding RANKL, denosumab reduces bone breakdown. The FDA approved it in 2010 for postmenopausal women with osteoporosis at high fracture risk, and it is given as a 60 mg subcutaneous injection every six months.

Prolia is also approved for bone loss associated with hormone ablation therapy in women with breast cancer, which means some women in their 40s and early 50s encounter it earlier than the typical postmenopausal context.

Who Gets Prescribed Prolia?

The women most commonly prescribed Prolia fall into three groups.

Postmenopausal women with osteoporosis. The landmark FREEDOM trial enrolled 7,868 postmenopausal women aged 60 to 90 and showed that denosumab reduced new vertebral fractures by 68% and hip fractures by 40% over three years compared with placebo. This remains the core evidence base.

Women receiving aromatase inhibitors for breast cancer. Estrogen suppression accelerates bone loss at rates of 2% to 3% per year at the lumbar spine. Denosumab counteracts this directly.

Perimenopausal women with glucocorticoid-induced bone loss. This is a smaller but growing group, particularly women on long-term corticosteroids for autoimmune conditions such as lupus or rheumatoid arthritis.

How Denosumab Works in a Female Hormonal Context

Estrogen normally suppresses RANKL expression in osteoblasts. When estrogen drops at menopause, RANKL activity rises, osteoclasts become more active, and bone resorption accelerates. Denosumab steps in exactly where estrogen stepped out. Research published in the Journal of Bone and Mineral Research confirms that postmenopausal bone loss is primarily RANKL-driven, which is why denosumab is so effective in this population.

What Is Glycine and Why Are Women Taking It?

Glycine is the simplest amino acid and a conditionally essential one. Your body produces roughly 3 g per day endogenously, but some estimates suggest metabolic needs may exceed 10 g per day, leaving a gap that dietary sources or supplements fill.

Women are taking glycine supplements for several reasons that often overlap with conditions common in midlife.

Sleep

Oral glycine at 3 g taken before bed shortened sleep onset and improved subjective sleep quality in a small randomized crossover trial (n=11). Sleep disruption is one of the most common complaints during perimenopause, which makes glycine an appealing option for women who want a non-hormonal sleep aid.

Blood Sugar Regulation

Glycine stimulates glucagon-like peptide-1 (GLP-1) secretion and may improve insulin sensitivity. A 2009 study in Regulatory Peptides showed that oral glycine ingestion increased plasma GLP-1 in healthy adults. For women with PCOS or prediabetes, who are also at elevated fracture risk due to metabolic bone effects, this glycemic angle is relevant.

Collagen Synthesis and Bone Matrix

Glycine makes up roughly one-third of all amino acids in collagen by mass. Type I collagen is the primary protein scaffold of cortical bone. Without adequate glycine, collagen crosslinking suffers, and bone matrix quality declines even when mineral density is maintained. A study in Osteoporosis International found that collagen peptide supplementation (which delivers glycine) improved bone mineral density at the femoral neck in postmenopausal women over 12 months when combined with calcium and vitamin D.

Glycine and PCOS

Women with PCOS show lower fasting glycine levels compared with controls, according to metabolomic data published in PLOS ONE. Because PCOS is associated with insulin resistance and, in some cases, suboptimal bone density in younger women, glycine supplementation has theoretical appeal in this group even before Prolia becomes relevant.

Does Glycine Interact with Prolia (Denosumab)?

No direct pharmacokinetic interaction has been identified. Denosumab is a monoclonal antibody, not a small molecule, so it bypasses the cytochrome P450 enzyme system entirely. It is not renally cleared in the traditional sense and does not affect hepatic drug metabolism. Glycine, an amino acid, is absorbed and metabolized through entirely separate pathways.

To be precise about interaction types:

Pharmacokinetic interaction (absorption, distribution, metabolism, excretion): No plausible mechanism exists. Denosumab's half-life of approximately 25 to 28 days after a 60 mg subcutaneous dose is driven by IgG-class antibody recycling via the neonatal Fc receptor, not by enzyme competition. Glycine does not touch that system.

Pharmacodynamic interaction (additive, synergistic, or antagonistic effects on the same endpoint): This is where the clinically meaningful questions sit, and the answer is nuanced rather than alarming.

Glycine's Effect on Bone: Potentially Additive

Denosumab reduces bone resorption. Glycine supports bone matrix synthesis by providing substrate for collagen. These two mechanisms act on different arms of bone remodeling: denosumab slows breakdown, glycine may support rebuilding. In theory, this is complementary rather than problematic. No head-to-head trial has tested this combination, but no mechanistic reason suggests glycine would blunt denosumab's anti-resorptive effect.

Glycine's Glycemic Effect: Worth Watching in Specific Women

Denosumab itself does not affect blood glucose in any clinically significant way in most women. But if you are also on a GLP-1 receptor agonist (semaglutide, liraglutide) because many women with obesity and osteoporosis overlap, glycine's GLP-1-stimulating property could add a small, additive glucose-lowering effect. This is not dangerous for most women, but if you are on insulin or a sulfonylurea alongside your Prolia, monitoring your glucose after starting glycine is reasonable.

Glycine's Sleep Effect: No Interaction with Denosumab

Glycine's sleep benefit operates through lowering core body temperature and possibly modulating NMDA receptor activity in the suprachiasmatic nucleus. Denosumab has no central nervous system activity. No interaction here.

Calcium Metabolism: One Practical Caution

Denosumab rapidly and substantially reduces bone resorption. After each injection, serum calcium can dip, and hypocalcemia is the most serious adverse effect of Prolia. The FDA label requires that you correct pre-existing hypocalcemia before starting and that you take calcium and vitamin D daily during treatment.

Glycine itself does not lower serum calcium. No evidence suggests it worsens hypocalcemia. But if you are relying on a collagen-peptide product as your glycine source rather than a pure glycine supplement, check whether that product also contains phosphorus-binding minerals that could affect calcium absorption. Pure glycine powder or capsules do not carry this risk.

Dosing and Timing: What You Actually Need to Know

Denosumab is given every six months by a clinician. You have no control over the pharmacokinetics of that injection once it is in. Glycine is taken orally daily.

No dose-separation window is needed. Because the two compounds do not share metabolic pathways, taking glycine on the same day as your Prolia injection or at any point in the six-month cycle is not pharmacologically problematic.

Practical dosing reference points, based on published human data:

| Purpose | Glycine dose studied | Duration | |---|---|---| | Sleep quality | 3 g before bed | Short-term (4 days in RCT) | | Metabolic / GLP-1 | 5 g with meals | Single-dose studies | | Collagen support (as collagen peptides) | 5 g to 10 g/day (delivers ~1.5 to 3 g glycine) | 12 months in bone trial | | Upper safe intake observed | Up to 31 g/day in schizophrenia trials with no serious adverse events |

For women taking glycine primarily for sleep or bone support while on Prolia, a dose of 3 g to 5 g per day is the most evidence-informed starting point.

Life-Stage Guide: Is This Combination Right for You?

Postmenopausal Women (the Primary Prolia Population)

This is where the evidence is strongest. Postmenopausal women on Prolia for osteoporosis can take glycine without a documented interaction concern. The priority checklist before adding glycine:

• Confirm you are taking adequate calcium (1,200 mg/day total from food and supplements) and vitamin D (800 to 1,000 IU/day minimum, per National Osteoporosis Foundation guidance) alongside Prolia.
• If you have chronic kidney disease (common in older postmenopausal women), glycine metabolism may be altered because the kidneys are a major site of glycine synthesis. Discuss with your nephrologist before starting.
• Sleep disruption in postmenopause is well-documented. If you are adding glycine for sleep, 3 g before bed is a reasonable starting dose.

Perimenopausal Women with Early Bone Loss

Prolia is not first-line for perimenopausal women with osteopenia. Hormone therapy, bisphosphonates, or lifestyle modification come first. If you are in this group and on Prolia for a specific indication (such as glucocorticoid use), glycine at 3 g to 5 g daily is reasonable and has no known interaction with denosumab.

Women with Breast Cancer on Aromatase Inhibitors

Aromatase inhibitor therapy causes significant bone loss, and Prolia is FDA-approved in this setting. Many women in this group are also managing fatigue and sleep difficulties from treatment. Glycine for sleep support at 3 g before bed has no interaction with denosumab and no known interaction with common aromatase inhibitors (anastrozole, letrozole, exemestane). Discuss with your oncology team before adding any supplement during active cancer treatment.

Reproductive-Age Women with PCOS

PCOS is associated with lower glycine levels and insulin resistance, and some women with PCOS have suboptimal bone density. If you are a younger woman with PCOS who has been prescribed denosumab (less common but possible in specific clinical scenarios), glycine supplementation has no known interaction concern with Prolia. The glycemic effect of glycine may offer a small additive benefit to insulin sensitization.

Pregnancy, Lactation, and Contraception

Denosumab is contraindicated in pregnancy. This is an absolute contraindication.

Denosumab crosses the placenta. In animal studies, maternal exposure to denosumab resulted in fetal lymph node agenesis, abnormal bone development, and increased postnatal mortality. The FDA label assigns it to former Pregnancy Category X equivalent under current labeling (causes fetal harm; risks outweigh benefits). If you become pregnant while on Prolia, contact your clinician immediately.

Because denosumab has a long half-life (approximately 25 to 28 days) and bone effects persist well beyond serum clearance, contraception must be reliable for at least five months after the last dose. Women of reproductive potential who are prescribed denosumab for cancer-related bone loss should discuss long-acting reversible contraception with their care team before starting.

Lactation. It is not known whether denosumab transfers into human breast milk. Given that it is a large IgG monoclonal antibody (molecular weight approximately 147 kDa), significant transfer into milk is unlikely, but no human lactation data exists. The prescribing information advises weighing the developmental and health benefits of breastfeeding against the mother's clinical need. Breastfeeding while on Prolia should be discussed individually with your prescriber and a lactation consultant.

Glycine in pregnancy and lactation. Glycine is classified as generally recognized as safe (GRAS) by the FDA. It is a natural component of protein-containing foods and is present in breast milk. No specific safety signals have been identified at typical supplement doses (3 g to 5 g/day) in pregnant or lactating women, but formal controlled trial data in these populations is absent. The risk here is low, but the denosumab contraindication in pregnancy means the clinical scenario of co-administration in a pregnant woman should not arise.

What to Do If You Are Already Taking Both

Many women start glycine before their clinician knows about it, because amino acid supplements are sold without prescription and often feel categorically "safe." If you are already taking glycine alongside Prolia, here is the practical guidance.

First, tell your prescribing clinician. Not because the combination is dangerous, but because a complete supplement list allows accurate clinical monitoring. Hypocalcemia after Prolia injections is real, and knowing your full supplement and dietary pattern helps your clinician interpret any lab abnormality correctly.

Second, confirm your calcium and vitamin D intake are adequate. Glycine does not substitute for calcium. If you are relying on a collagen product for joint or skin support and counting it as your calcium source, that is a gap. Collagen is not a calcium supplement.

Third, if you notice any of these symptoms in the days to weeks after a Prolia injection, contact your clinician: muscle cramps, numbness or tingling around the mouth or fingertips, irregular heartbeat, or severe fatigue. These may signal hypocalcemia, which has nothing to do with glycine but which requires prompt attention.

Fourth, if you have kidney disease or a history of low calcium, your clinician may want to check serum calcium and phosphorus levels before and after your first few Prolia injections. Glycine does not worsen this risk, but it does not protect against it either.

Monitoring Checklist for Women on Prolia Adding Glycine

• Serum calcium and vitamin D levels: check before each Prolia injection (standard of care regardless of glycine).
• Blood glucose: relevant only if you are also on insulin, a sulfonylurea, or a GLP-1 receptor agonist. Monitor fingerstick or fasting glucose for two weeks after starting glycine.
• Kidney function: if eGFR <45 mL/min/1.73m2, discuss glycine metabolism with your nephrologist before starting.
• Sleep diary: if using glycine for sleep, a one-week baseline and a two-week post-start diary helps you judge whether 3 g is effective or whether dose adjustment is warranted.
• Bone density: DXA scan every one to two years on Prolia, per ACOG and The Menopause Society guidance. Glycine supplementation does not alter DXA interpretation.

What the Evidence Gap Means for You

Women have been historically underrepresented in supplement-drug interaction research. No published randomized trial has examined glycine co-administration with any monoclonal antibody, let alone denosumab specifically. The reassurance that no interaction exists is based on mechanistic reasoning and the general safety profile of glycine, not on a head-to-head trial. That distinction matters.

The FREEDOM trial enrolled women aged 60 to 90 and did not systematically capture supplement use, so we cannot extract real-world co-administration data from it. The glycine-bone trial in postmenopausal women (delivered as collagen peptides) published in Osteoporosis International did not include women on antiresorptive therapy.

This is an honest gap. If you want a definitive answer backed by a clinical trial, that trial has not been done. What exists is sound mechanistic reasoning, a favorable glycine safety profile across a wide dose range, and no plausible pathway for harm from co-administration.

Rachel Goldberg, MD, WomanRx clinical reviewer, notes: "In my practice, postmenopausal women on Prolia often ask about sleep supplements, and glycine comes up frequently. I don't see a mechanism for harm with co-administration, and I do see potential benefit for sleep and collagen support. My standard advice is to confirm calcium and vitamin D are locked in first, then add glycine at 3 g before bed if sleep is the goal."

Conditions Denosumab Touches in Women

Beyond postmenopausal osteoporosis, denosumab is relevant to women across several conditions.

Breast cancer with bone metastases. A higher-dose formulation (Xgeva, 120 mg every four weeks) is used here. Glycine interaction considerations are the same; the hypocalcemia risk is heightened at higher doses.

Glucocorticoid-induced osteoporosis. Women with lupus, rheumatoid arthritis, or inflammatory bowel disease on long-term prednisone develop bone loss rapidly. Denosumab is an option in this group, and glycine's collagen-support mechanism has theoretical appeal alongside it.

Female pattern hair loss. Glycine is promoted in some circles as a collagen-precursor supplement for hair. Denosumab has no known effect on hair. The combination in this context has no interaction concern.

Hormonal acne and PCOS. Women with PCOS taking inositol, metformin, or spironolactide alongside any bone medication should have their supplement list reviewed as a whole. Glycine does not interact with those agents at typical doses either, but the full picture matters to the clinician managing your care.